Article
Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes.
Oncogene - 1 Nov 2021
Lebedev Timofey, Vagapova Elmira, Spirin Pavel, Rubtsov Petr, Astashkova Olga, Mikheeva Alesya, Sorokin Maxim, Vladimirova Uliana, Suntsova Maria, Konovalov Dmitry, Roumiantsev Alexander, Stocking Carol, Buzdin Anton, Prassolov Vladimir
Abstract excerpt
Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers, which hinders the development of targeted therapies and novel risk stratification strategies. Multikinase inhibitors have shown potential in treating high-risk NB, but their efficacy is likely impaired by the cancer cells' ability to adapt to these drugs through the employment of alternative signaling pathways. Based on the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.